Third Harmonic Bio logo

Third Harmonic BioNASDAQ: THRD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 September 2022

Website:

http://www.thirdharmonicbio.com

Next earnings report:

09 August 2024

Last dividends:

N/A

Next dividends:

N/A

Market cap

$505.32 M
-46%vs. 3y high
67%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

1.92
-39%vs. 3y high
55%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

after hours | Thu, 20 Jun 2024 20:20:04 GMT
$12.34-$0.13(-1.04%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$0.20-$0.27

Revenue

Revenue target

--
No data over the past 3 years

Revenue

Net income

--$7.86 M

Analysts recommendations

Total assets

Total liabilities

$270.52 M$7.02 M

Institutional Ownership

Included in screeners

Small cap companies
Stocks with low beta
Analysts recommendations: buy
Price lower than analysts target
Stocks with high Altman Z score
Growing shares outstanding

Similar companies

Quanterix logo

Quanterix (QTRX)

ArriVent BioPharma Common Stock (AVBP)

SI-BONE logo

SI-BONE (SIBN)

Applied Therapeutics logo

Applied Therapeutics (APLT)

Lyell Immunopharma logo

Lyell Immunopharma (LYEL)

Cross Country Healthcare logo

Cross Country Healthcare (CCRN)

Paragon 28 logo

Paragon 28 (FNA)

Savara logo

Savara (SVRA)

THRD Latest News

Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
GlobeNewsWire31 August 2023 Sentiment: POSITIVE

SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2023, from 7:30-7:55 a.m. ET.

What type of business is Third Harmonic Bio?

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.

What sector is Third Harmonic Bio in?

Third Harmonic Bio is in the Healthcare sector

What industry is Third Harmonic Bio in?

Third Harmonic Bio is in the Biotechnology industry

What country is Third Harmonic Bio from?

Third Harmonic Bio is headquartered in United States

When did Third Harmonic Bio go public?

Third Harmonic Bio initial public offering (IPO) was on 14 September 2022

What is Third Harmonic Bio website?

https://www.thirdharmonicbio.com

Is Third Harmonic Bio in the S&P 500?

No, Third Harmonic Bio is not included in the S&P 500 index

Is Third Harmonic Bio in the NASDAQ 100?

No, Third Harmonic Bio is not included in the NASDAQ 100 index

Is Third Harmonic Bio in the Dow Jones?

No, Third Harmonic Bio is not included in the Dow Jones index

When does Third Harmonic Bio report earnings?

The next expected earnings date for Third Harmonic Bio is 09 August 2024